U.S. Markets open in 8 hrs 44 mins

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
47.710.00 (0.00%)
At close: 4:02PM EDT
People also watch
NVSGSKAZNLLYNVO
Full screen
Previous Close47.71
Open47.71
Bid0.00 x
Ask0.00 x
Day's Range47.51 - 47.85
52 Week Range36.81 - 50.24
Volume1,179,870
Avg. Volume1,929,665
Market Cap111.61B
Beta0.76
PE Ratio (TTM)11.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.64 (3.41%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters11 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacks3 days ago

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

  • Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
    Zacks4 days ago

    Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

    Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.